Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc.
Therapy for infection with HIV-2 remains limited. We report an HIV-2-infected patient in whom genotyping demonstrated PI, NRTI and NNRTI resistance, with a subsequent response to raltegravir- and maraviroc-based therapy. Further studies are required to assess the clinical efficacy of maraviroc in HIV-2 infection.
Armstrong-James
Darius
D
Imperial College, St. Stephens AIDS Trust, Chelsea and Westminster Hospital, London, UK.
Stebbing
Justin
J
Scourfield
Andrew
A
Smit
Erasmus
E
Ferns
Bridget
B
Pillay
Deenan
D
Nelson
Mark
M
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D003510:Cyclohexanes / Q000627:therapeutic use*; D024882:Drug Resistance, Viral; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology*; D015498:HIV-2 / Q000302:isolation & purification*; D006801:Humans; D000077592:Maraviroc; D011760:Pyrrolidinones / Q000627:therapeutic use*; D012367:RNA, Viral / Q000235:genetics; D000068898:Raltegravir Potassium; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*
D019380:Anti-HIV Agents; D003510:Cyclohexanes; D011760:Pyrrolidinones; D012367:RNA, Viral; D014230:Triazoles; D000068898:Raltegravir Potassium; D000077592:Maraviroc